









Nan

Name: Age/Gender 41 years 1 month 6 days/Female

Referred By N.A Client Name

**Collection Date:** 28-02-2018 00:00:00 **Report Release Time** 10-03-2018 11:15:59

Section	Details	Section Id
Section 1	Vitamin B12 and folic acid metabolism	R1
Section 2	Vitamin Metabolism	R2
Section 3	Fatty Acid Metabolism	R3
Section 4	Carbohydrate Metabolism	R4
Section 5	Gut Dysbiosis	R5
Section 6	Detoxification Health	R6
Section 7	Energy Production Metabolism	R7
Section 8	Protein Intake, Muscle Catabolism and Oxalate metabolism	R8
Section 9	Mineral Sufficiency	R9
Section 10	Amino Acid Sufficiency	R10

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:15:59

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)









# www.fmdiagnostics.com A unit of Functional Medicine InstitutePvt. Ltd.

099605000

Name: Grethel Marie Samudio Gonzalez

Referred By N.A

**Collection Date:** 28-02-2018 00:00:00

Age/Gender 41 years 1 month 6 days/Female

Client Name Global Biotech Solutions - Panama

**Report Release Time** 10-03-2018 11:15:59

## **Report Summary**

Sr.No	CONDITION		STATUS	
R.8 1	Kidney Stone Risk	O Absent	Mild	O Severe

Mild hyperoxaluria may be due to excess intake of tea, spinach or vitamin C supplements. Low calcium diet may promote hyperoxaluria as less calcium is available to bind dietary oxalate which is left free for absorption. Pyroxine supplements, enough water intake and dietary changes like salt restriction and avoiding food items containing oxalates.

Patient Name: Patient ID: 509660













#### Interpretation R.1 -Vitamin B12 and folic acid metabolism

Sr.No	CONDITION		STATUS	
R.1 1	Vitamin B12	Sufficient	O BorderLine	O Deficient
R.1 2	Folate	Sufficient	O BorderLine	O Deficient

#### Section R.1-Vitamin B12 and folic acid metabolism

B-vitamins improve/manage the nervous system and brain functions. Optimizing folic acid and vitamin B12 intake is of profound benefit to cognitive ability as well as help maintain optimal function of nerves at every age. These nutrients are crucial for the proper function of various metabolic pathways, especially those involved with the healthy function of nerves. Folic acid is needed to metabolize homocysteine. B12 is needed to metabolize methylmalonic acid. It is important to monitor Folic acid and B12 during aging, as elevations in either homocysteine or methylmalonic acid are known to impair brain function and lead to age related cognitive decline.

Sr.No	o Investigation	Observed Value	Reference Range	Risk Graph		
Vita	Vitamin B12 and folic acid metabolism					
Bloc	od Markers	Unit - nmol/1	ml			
1	Glycine	269.4319	126.00 - 490.00	•		
2	Beta-AminoIsoButyric Acid	0.6956	0.00 - 5.00	•		
3	Sarcosine	4.2680	0.00 - 5.00	•		
4	Histidine	47.09	39.00 - 123.00	•		
Urin	ary Markers	Unit - mmol/	/mol Cr			
1	MMA	0	0.0 - 10.41			
2	Uracil	0.01	0.0 - 4.06	•		
3	Formiminoglutamate	55.71	1.1 - 208.08	•		

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:15:59

Patient Name:
Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 3 of 18

<sup>\*</sup> The analyte is not in the lab scope.









## **Interpretation R.2 -Vitamin Metabolism**

Sr.No	CONDITION		STATUS	
R.2 1	Vitamin B1	Sufficient	O BorderLine	O Deficient
R.2 2	Vitamin B3	Sufficient	O BorderLine	O Deficient
R.2 3	Vitamin B5	Sufficient	O BorderLine	O Deficient
R.2 4	Vitamin B6	Sufficient	O BorderLine	O Deficient
R.2 5	Vitamin E	Sufficient	O BorderLine	O Deficient
R.2 6	Vitamin K	Sufficient	O BorderLine	O Deficient
R.2 7	Biotin	Sufficient	O BorderLine	O Deficient

#### Section R.2-Vitamin Metabolism

Vitamin B12 is a water-soluble vitamin which plays a key role in the normal functioning of the brain, nervous system, and formation of blood. Vitamin B12 deficiency is highly prevalent among patients with type 1 and type 2 diabetes mellitus and may lead to ipaired memory, dementia, peripheral neuropathy and similar complications. There is a specific panel of metabolic markers indicates Vitamin B12 deficiency and helps alter the drug regime for the diabetic. Similarly, there are markers studies for Manganisium deficiency. Manganisium helps regulate blood sugar levels, promotes normal blood pressure, and hence is an important mineral to be maintained in appropriate levels in a diabetic.

Sr.No	o Investigation	Observed Value	Reference Range		Risk Graph	
Vita	min Metabolism					
Bloc	od Markers	Unit - nmol/1	ml			
1	Serine	114.85	63.00 - 187.00		•	
2	Sarcosine	4.2680	0.00 - 5.00		•	
3	Carnosine	0.1200	0.00 - 1.00	9		
4	Beta-AminoIsoButyric Acid	0.6956	0.00 - 5.00	•		
5	beta-Alanine	1.9853	0.00 - 29.00	9		
6	Threonine	212.66	85.00 - 231.00		•	

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:15:59

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 4 of 18

<sup>\*</sup> The analyte is not in the lab scope.



A unit of Functional Medicine InstitutePvt. Ltd.







Sr.No Investigation Observed Value Reference Range Risk Graph

#### Vitamin Metabolism

Urin	ary Markers	Unit - mm	nol/mol Cr	
1	Suberate	0.01	0.0 - 2.33	
2	Gln	0	0.0 - 4.54	•
3	HMG2	1.25	0.06 - 3.79	•
4	EMA	0	0.0 - 7.68	•
5	Leu	0	0.0 - 2.98	•
6	Pyruvate	0.02	0.0 - 4.24	
7	Succinate	2.51	0.03 - 2.68	•
8	isoLeu	0	0.0 - 4.28	•
9	Adipate	0.29	0.11 - 2.76	• • • • • • • • • • • • • • • • • • •
10	3HIV	0.05	0.0 - 4.48	•
11	PyroGlu	1.49	0.66 - 8.56	
12	Malate	0.51	0.03 - 6.09	•
13	Glutarate	0	0.0 - 14.15	•
14	Xanthurenic acid	82	1.1 - 208.08	•

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:00

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

<sup>\*</sup> The analyte is not in the lab scope.









#### **Interpretation R.3 - Fatty Acid Metabolism**

Sr.No	CONDITION		STATUS	
R.3 1	Fatty Acid - Omega Oxidation	Normal	O Impaired	O Severe
R.3 2	Carnitine Status	Sufficient	O BorderLine	O Deficient
R.3 3	Mitochondial Dysfunction	Normal	O Impaired	O Severe

## Section R.3-Fatty Acid Metabolism

Carnitine helps our body use fatty acids. The body makes small amounts of carnitine. However, if minimum requirements are not met, carnitine dependent functions fail to proceed normally. Long-chain fatty acids go through beta-oxidation in the mitochondria, which is a carnitine dependent step.

Sr.No	o Investigation	Observed Value	Reference Range	Risk Graph
Fatt	y Acid Metabolism			
Blood Markers		Unit - nmol/	ml	
1	C0	46.33	11.00 - 49.00	•
Urin	nary Markers	Unit - mmol	/mol Cr	
1	Me-succinate	0	0.0 - 0.1	10
2	Adipate	0.29	0.11 - 2.76	10
3	Suberate	0.01	0.0 - 2.33	•
4	EMA	0	0.0 - 7.68	•
5	sebacate	0	0.0 - 0.1	

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:00

Patient Name:
Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 6 of 18

<sup>\*</sup> The analyte is not in the lab scope.









## **Interpretation R.4 - Carbohydrate Metabolism**

Sr.No	CONDITION		STATUS	
R.4 1	Carbohydrate Metabolism	Normal	O Impaired	O Severe
R.4 2	Chromium picolinate	Sufficient	O BorderLine	O Deficient
R.4 3	Glucose oxidation Impairment	Normal	O Impaired	O Severe

## Section R.4-Carbohydrate Metabolism

Lactate and Pyruvate elevates when there is deficiency in Krebs Cycle. When carbohydrate are available because of fasting or low carbohydate diet, ketones bodies are formed.

Sr.N	o Investigation	Observed Value	Reference Range	Risk Graph	
Carbohydrate Metabolism					
Urir	nary Markers	Unit - mmol/	mol Cr		
1	Pyruvate	0.02	0.0 - 4.24		
2	Lactate	66.69	1.1 - 208.08	•	
3	2KG	0	0.0 - 0.1	•	
4	3НВ	0	0.0 - 0.1		

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:00

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 7 of 18









## **Interpretation R.5 - Gut Dysbiosis**

Sr.No	CONDITION		STATUS	
R.5 1	Dysbiosis Markers	Absent	O Mild	O Severe
R.5 2	Dysbiosis Risk	Absent	O Mild	O Severe
R.5 3	Gut Permeability	Absent	O Mild	O Severe
R.5 4	Intestinal malabsorption	Absent	O Mild	O Severe
R.5 5	Clostridia Bacterial Overgrowth	Absent	O Mild	O Severe
R.5 6	Yeast and Fungal Infection	Absent	O Mild	O Severe
R.5 7	Bacterial Overgrowth	Absent	O Mild	O Severe

#### **Section R.5-Gut Dysbiosis**

A leaky gut is a situation when spaces form between the cells in the small intestinal wall allow large molecules (Eg. food, bacteria, heavy metals, toxins, and allergens) sneak through to blood stream, thereby triggering a response by body's immune system. Type 2 Diabetes is commonly associated with poor diet and inactivity, which could be an outcome of a leaky gut. Predominance of bad types of bacteria the digestive system is called as Dysbiosis. Type 2 diabetes is almost always associated with colonic dysbiosis and it is important to check whether there is a dysbiosis situation with a diabetic.

Sr.No Investigation	Observed Value	Reference Range	Risk Graph
Gut Dysbiosis			
Blood Markers	Unit - nmol	/ml	
1 beta-Alanine	1.9853	0.00 - 29.00	•
2 Valine	155.13	136.00 - 309.00	•
3 Threonine	212.66	85.00 - 231.00	•
Urinary Markers	Unit - mmo	l/mol Cr	
1 Benzonate	0	0.0 - 3.78	

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:00

Patient Name: Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 8 of 18

<sup>\*</sup> The analyte is not in the lab scope.









# www.fmdiagnostics.com A unit of Functional Medicine InstitutePvt. Ltd.

	Observed Value	Reference Range	Risk Graph

#### Gut Dysbiosis

Dysulosis			
ary Markers			
4HPA	2.49	0.13 - 8.66	•
2HIC	0	0.0 - 0.1	•
Indole3AA	0	0.0 - 0.1	
ЗНРЗНР	0.02	0.0 - 4.35	
4HBA	0	0.0 - 3.63	•
2Hhippurate	0	0.0 - 4.81	•
5HM2F	0	0.0 - 4.36	
tartarate	0	0.0 - 0.1	•
4HPL	0	0.0 - 0.1	•
2HPA	0	0.0 - 0.1	io i
hippurate1	0	0.0 - 13.81	•
4Hhippurate	0	0.0 - 10.1	•
	2HIC Indole3AA 3HP3HP 4HBA 2Hhippurate 5HM2F tartarate 4HPL 2HPA hippurate1	ary Markers  4HPA 2.49  2HIC 0  Indole3AA 0  3HP3HP 0.02  4HBA 0  2Hhippurate 0  5HM2F 0  tartarate 0  4HPL 0  2HPA 0  hippurate 1	ary Markers  4HPA  2.49  0.13 - 8.66  2HIC  0  0.0 - 0.1  Indole3AA  0  0.02  0.0 - 4.35  4HBA  0  0.0 - 3.63  2Hhippurate  0  0.0 - 4.81  5HM2F  0  0.0 - 4.36  tartarate  0  0.0 - 0.1  4HPL  0  0.0 - 0.1  2HPA  0  0.0 - 0.1  hippurate1

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:00

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)









## **Interpretation R.6 -Detoxification Health**

Sr.No	CONDITION		STATUS	
R.6 1	Ammonia Detoxification	Normal	O Impaired	O Severe
R.6 2	Hepatic detoxication	Normal	O Impaired	O Severe
R.6 3	Glutathione Status	Normal	O Impaired	O Severe

#### **Section R.6-Detoxification Health**

Orotate is sensitive to anything that increases ammonia, including a high protein diet, intestinal dysbiosis, or arginine deficiency. This leads to increased orotate urinary values. Glutathione is an important antioxidant that helps protect against reactive oxygen species such as free radicals. Glutathione is constantly used up in the removal of toxic molecules and prevention of oxidative damage.

Sr.N	o Investigation	Observed Value	Reference Range	Risk Graph
Deta	exification Health			
Bloc	od Markers	Unit - nmol/r	nl	
1	Taurine	140.81	46.00 - 146.00	
2	beta-Alanine	1.9853	0.00 - 29.00	
3	Glutamine	574.85	428.00 - 747.00	•
Urin	ary Markers	Unit - mmol/	mol Cr	
1	PyroGlu	1.49	0.66 - 8.56	•
2	Mandelate	0	0.0 - 16.06	•
3	Orotate	0	0.0 - 19.3	•

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:01

Patient Name: Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 10 of 18

<sup>\*</sup> The analyte is not in the lab scope.









## **Interpretation R.7 - Energy Production Metabolism**

Sr.No	CONDITION		STATUS	
R.7 1	Coenzyme Q10	Sufficient	O BorderLine	O Deficient
R.7 2	Lipoic Acid	Sufficient	O BorderLine	O Deficient

# **Section R.7-Energy Production Metabolism**

Coenzyme Q10 and Lipoic modulates the Krebb cycle to use energy inside the cells. Impairment can lead to fatigue and impaired glucose homeostasis.

Sr.No	Investigation	Observed Value	Reference Range	Risk Graph
Energ	gy Production Metabo	lism		
Blood	d Markers	Unit - nmol/r	nl	
1	Valine	155.13	136.00 - 309.00	-
2	C0	46.33	11.00 - 49.00	•
Urina	ary Markers	Unit - mmol/	mol Cr	
1	Analog Cit	0	0.0 - 4.74	•
2	Citrate	0	0.0 - 4.12	•
3	HMG2	1.25	0.06 - 3.79	•
4	Malate	0.51	0.03 - 6.09	•
5	Succinate	2.51	0.03 - 2.68	•
6	Cisaconate	0.01	0.0 - 2.95	

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:01

Patient Name: Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 11 of 18

<sup>\*</sup> The analyte is not in the lab scope.









#### Interpretation R.8 -Protein Intake, Muscle Catabolism and Oxalate metabolism

Sr.No	CONDITION				STATUS	
R.8 1	Kidney Stone Risk	0	Absent	0	Mild	O Severe
R.8 2	Muscles Turnover		Sufficient	0	BorderLine	O Deficient
R.8 3	Protein Intake Status		Sufficient	0	BorderLine	O Deficient

## Section R.8-Protein Intake, Muscle Catabolism and Oxalate metabolism

Amino acids levels in plasma indicates long term protein intake status. Oxalate and methyl-histidine in urine are markers of muscle catabolism and Kidney stone risk.

Blood Markers	Unit - nmol	/ml	
1 Histidine	47.09	39.00 - 123.00	•
2 Glycine	269.4319	126.00 - 490.00	•
3 1- Methyl-histidine	7.46	3.00 - 9.00	•
4 Cysteine	268.64	100.00 - 300.00	
5 Lysine	165.05	152.00 - 247.00	
6 Proline	154.15	97.00 - 368.00	

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:01

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 12 of 18

<sup>\*</sup> The analyte is not in the lab scope.









## **Interpretation R.9 - Mineral Sufficiency**

Sr.No	CONDITION		STATUS	
R.9 1	Magnesium	Sufficient	O BorderLine	O Deficient
R.9 2	Selenium	Sufficient	O BorderLine	O Deficient
R.9 3	Carnitine	Sufficient	O BorderLine	O Deficient
R.9 4	N-Acetylcysteine	Sufficient	O BorderLine	O Deficient
R.9 5	Iron	Sufficient	O BorderLine	O Deficient
R.9 6	Zinc	Sufficient	O BorderLine	O Deficient

#### **Section R.9-Mineral Sufficiency**

Minerals are crucial elements of the biological processes that are required for well-being of the body. Mineral deficiencies lead to a weakened ability to regulate glucose levels, detoxification and mental well-being. Supplementing with high quality, bioavailable minerals improves the body's ability to regulate body detoxification, protein, fat and carbohydrate metabolism. To reduce inflammation and oxidative damage, key antioxidants and minerals are key to fighting these inflammatory and destructive reactions.

Sr.N	o Investigation	Observed Value	Reference Range	Risk Graph
Min	eral Sufficiency			
Bloo	od Markers	Unit - nmol/	ml	
1	Lysine	165.05	152.00 - 247.00	•
2	Histidine	47.09	39.00 - 123.00	•
3	Glycine	269.4319	126.00 - 490.00	•
4	beta-Alanine	1.9853	0.00 - 29.00	
5	Threonine	212.66	85.00 - 231.00	0
Urin	ary Markers	Unit - mmol	/mol Cr	
1	b-Ala	0	0.0 - 11.31	•
2	Leu	0	0.0 - 2.98	•

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:01

Patient Name: Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 13 of 18

<sup>\*</sup> The analyte is not in the lab scope.





0

0





# A unit of Functional Medicine InstitutePvt. Ltd.

8

9

Phe1

Lys1

	o Investigation	Observed Value	Reference Range	Risk Graph
Min	eral Sufficiency			
Urin	ary Markers			
3	Ser1	0	0.0 - 5.28	•
4	isoLeu	0	0.0 - 4.28	•
5	Thr	0	0.0 - 4.53	•
6	His	0	0.0 - 7.1	•
7	Gly1	5.76	0.12 - 7.72	•

0.0 - 7.91

0.0 - 3.88

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:02

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 14 of 18









## **Interpretation R.10 - Amino Acid Sufficiency**

Sr.No	CONDITION		STATUS	
R.10 1	Arginine	Sufficient	O BorderLine	O Deficient
R.10 2	Tyrosine	Sufficient	O BorderLine	O Deficient
R.10 3	TryptoPhan	Sufficient	O BorderLine	O Deficient
R.10 4	Threonine	Sufficient	O BorderLine	O Deficient
R.10 5	Histidine	Sufficient	O BorderLine	O Deficient
R.10 6	Phenylalanine	Sufficient	O BorderLine	O Deficient
R.10 7	Valine	Sufficient	O BorderLine	O Deficient
R.10 8	Methionine	Sufficient	O BorderLine	O Deficient
R.10 9	Leucine	Sufficient	O BorderLine	O Deficient
R.10 10	Lysine	Sufficient	O BorderLine	O Deficient

# **Section R.10-Amino Acid Sufficiency**

Amino acids are the building blocks of proteins and modulate enregy production, detoxification and other essential functions in the body. Optimum levels of essential amino acids are required for a health body.

Sr.N	o Investigation	Observed Value	Reference Range	Risk Graph	
Amino Acid Sufficiency					
Bloc	od Markers	Unit - nmol/n	าใ		
1	Histidine	47.09	39.00 - 123.00	-	
2	Lysine	165.05	152.00 - 247.00		
3	Arginine	69.92	32.00 - 120.00	• • •	
4	Phenylalanine	44.0201	33.00 - 97.00		
5	Methionine	21.7141	11.00 - 44.00	<b>1</b>	
6	Valine	155.13	136.00 - 309.00	•	
7	Tyrosine	81.4750	0.00 - 90.00	•	

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:02

Patient Name: Patient ID: 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory
Dr. Mahesh Hampe
MD (Biochemistry)

Page 15 of 18

<sup>\*</sup> The analyte is not in the lab scope.



A unit of Functional Medicine InstitutePvt. Ltd.







Sr.No	Investigation	Observed Value	Reference Range	Risk Graph
Amino Acid Sufficiency				
Blood Markers				

8	Tryptophan	49.29	29.00 - 77.00	•
9	Threonine	212.66	85.00 - 231.00	•
10	Leucine	78.7552	68.00 - 183.00	•

#### **End Of Report**

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:02

Patient Name : Patient ID : 509660



Authorized Signatory Dr. Pramod Ingale MD (Biochemistry)



Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 16 of 18









#### **Understanding your report**

In the technical report section, you will see the graphic representation of all metabolic markers in the scope of the test conducted on your sample(s) and interpreted by our metabolic experts. The metabolic markers have been clubbed under various classes like - Carbohydrate Metabolism, Fatty Acid Metabolism, Vitamins Metabolism, Muscles Catabolism etc.

#### **Definitions**

<u>Metabolites</u> - Metabolites in your blood/urine samples are the Markers of Metabolism and act as the 'health indicators'. They characterize your state of metabolism and help make inferences in case of non-specific health conditions which can be an outcome of problems with your metabolism. Tracking the levels of these metabolites is important to ensure that early signals of diabetes related complications can be picked up.

Control Values - The 'Normal Limit' within which the value of a metabolic marker should ideally fall.

Observed (your) Value - The 'Actual Value' of a Metabolic Marker in your sample.

#### **Understanding the Risk-Bar**

<u>Risk Bar</u> - The horizontal bar as a pictorial representation of the observed values of the metabolic markers against the control values.


<u>Safe Zone (Green Color)</u>- If the value of markers measured in your sample fall in this region (signified by the green zone), you can relax and maintain the lifestyle you have.

<u>Risk Zone (Red Color)</u> - If the value of marker(s) measured in your sample falls in this region (signified by the red zone), it will be a matter of concern. You must consult your family physician or a metabolism expert.

<u>Medium Zone (color transition zone)</u> - If the value of a marker measured in your sample falls in this region (signified by the color transition from green to red), you may need to bring in changes in your lifestyle, diet or medication, depending on the particular case. Any modifications, however, have to be routed through a medical practitioner.

ND - Non Detected. This implies that the marker was not detected; and hence not to be considered in the Risk Zone.

Pointer - The 'blue dot' on the risk bar. It represents the actual value of a particular metabolic marker found in your sample.



The "Risk-Bars" have multiple color codes.

A. Green (safe) Zone on left and Red (Risk) Zone on right end implies that the normal values of your metabolic marker should be on left side of the risk bar. Higher values imply risk.

B. Red (Risk) Zone on both ends imply that the normal value of your metabolic marker should be in the middle part of risk bar. Lower than control value or higher than control value, will both imply a risk.

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date :10-03-2018 11:16:02

Patient Name: Patient ID: 509660 lite.

Authorized Signatory Dr. Pramod Ingale MD (Biochemistry) W.T

Authorized Signatory
Dr. Mahesh Hampe
MD (Biochemistry)

Page 17 of 18









#### References

- Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123(10):4309-17.
- Padberg I, Peter E, Gonzalez-Maldonado S, Witt H, Mueller M, Weis T et al. A new metabolomic signature in type-2 diabetes mellitus and its pathophysiology. PLoS One. 2014;9(1):e85082.
- Reinehr T, Wolters B, Knop C, Lass N, Hellmuth C, Harder U et al. Changes in the serum metabolite profile in obese children with weight loss. Eur J Nutr. 2015;54(2):173-81.
- Valcarcel B, Ebbels TM, Kangas AJ, Soininen P, Elliot P, Ala-Korpela M et al. Genome metabolome integrated network analysis to uncover connections between genetic variants and complex traits: an application to obesity. J R Soc Interface. 2014 Feb 26;11(94):20130908.
- Cupisti A, Meola M, D'Alessandro C, Bernabini G, Pasquali E, Carpi A, Barsotti G. Insulin resistance and low urinary citrate excretion in calcium stone formers. Biomed Pharmacother. 2007 Jan;61(1):86-90.
- Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nature Medicine 2011; 17(4):448–453.
- Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311-26.
- Xie B, Waters MJ, Schirra HJ. Investigating potential mechanisms of obesity by metabolomics. J Biomed Biotechnol. 2012;2012:805683.
- Du F, Virtue A, Wang H, Yang XF. Metabolomic analyses for atherosclerosis, diabetes, and obesity. Biomark Res. 2013 Apr 1;1(1):17.
- Lucio M, Fekete A, Weigert C, Wägele B, Zhao X, Chen J et al. Insulin sensitivity is reflected by characteristic metabolic fingerprints--a Fourier transform mass spectrometric non-targeted metabolomics approach. PLoS One. 2010;5(10):e13317.
- Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr. 2011 Nov;2(6):445-56.
- Du F, Virtue A, Wang H, Yang XF. Metabolomic analyses for atherosclerosis, diabetes, and obesity. Biomark Res. 2013 Apr 1;1(1):17.
- Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012;35(3):605-11.
- Lustgarten MS, Price LL, Phillips EM, Fielding RA. Serum glycine is associated with regional body fat and insulin resistance in functionally-limited older adults. PLoS One. 2013;8(12):e84034.





We welcome all questions and concerns. The questions pertaining to your analysis shall be answered by our experts (medical / nutritional).

You may post your queries on - info@preventine.com. Please mention your Name, Date of Birth and the Customer ID in the query.



Customer satisfaction is our core goal. It is important for us to learn about what our customers think about our service and how we can improve it. If you have any suggestion or complaint, whatsoever, we request you to contact us and report it on:

Email: <u>info@preventine.com</u> Contact: +91-22-61980000

#### Notes:

This report contains confidential medical information and genetic data. The report is for exclusive use by the person whose test has been conducted and the associated registered health practitioner. The report is copyright held by PreventiNe Life Care (P) Ltd.

\* The analyte is not in the lab scope.

CRM No:509660

Sample Received Time:05-03-2018 18:20:52 Report Release Date:10-03-2018 11:16:02

Patient Name: Patient ID: 509660 lite.

Authorized Signatory Dr. Pramod Ingale MD (Biochemistry) Authorized 6

Authorized Signatory Dr. Mahesh Hampe MD (Biochemistry)

Page 18 of 18